Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/23
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)GlobeNewsWire • 05/08/23
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/21/23
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual MeetingGlobeNewsWire • 03/02/23
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive TeamGlobeNewsWire • 12/15/22
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSPGlobeNewsWire • 12/14/22
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/22
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSPGlobeNewsWire • 11/02/22
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSPGlobeNewsWire • 11/01/22
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 202224/7 Wall Street • 10/25/22
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should KnowZacks Investment Research • 09/14/22
Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 09/01/22
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%Zacks Investment Research • 08/29/22
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to TradeZacks Investment Research • 08/12/22
Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/22
Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/02/22
Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022GlobeNewsWire • 08/01/22